Aurobindo’s Unit 1 clears USFDA audit with zero observations

Smart Money Financial Services :-

Aurobindo’s Unit 1 has cleared USFDA inspection with zero observations. Unit 1 is an API unit with manufacturing capabilities in CVS, CNS, anti-allergics and non-sterile Cephalosporins. The audit started on April 16 and ended on April 20, 2018.

Aurobindo Pharma Ltd is currently trading at Rs637.40 up by Rs18.9 or 3.06% from its previous closing of Rs618.50 on the BSE.


Comments

Popular posts from this blog

Top intraday trading ideas for afternoon trade for Monday 31 December 2018

F&O: Put writing at all immediate strikes shows Nifty may hold up

WELCOME TO SMART MONEY FINANCIAL SERVICES